Apremilast

Manufactured directly by Polpharma, this Apremilast (CAS 608141-41-9, Polymorphic Form B) is the active ingredient behind Otezla, a PDE4 inhibitor used to treat plaque psoriasis, psoriatic arthritis, and Behçet's disease by raising intracellular cAMP levels to reduce inflammation; it is FDA-approved and not yet available generically. Polpharma notes EU, US, and Canadian DMF readiness, and its listing carries a disclaimer that certain SPC-protected products from the company are produced solely for regulatory/R&D purposes or for export to non-EU markets where patent protection does not apply. It is distributed globally across the Americas, Europe, Australasia, Asia, the Middle East, and Africa.